Cart
sales@molnova.com
BIX02188 (c)
CAS No. 1094614-84-2
BIX02188 (c)( —— )
Catalog No. M10367 CAS No. 1094614-84-2
BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 54 | In Stock |
|
| 5MG | 115 | In Stock |
|
| 10MG | 217 | In Stock |
|
| 25MG | 327 | In Stock |
|
| 50MG | 491 | In Stock |
|
| 100MG | 707 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIX02188 (c)
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM.
-
DescriptionBIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorERK5| MEK1| MEK2| MEK5| TGFβR1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1094614-84-2
-
Formula Weight412.48
-
Molecular FormulaC25H24N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 100 mM
-
SMILESCN(C)CC1=CC(=CC=C1)N/C(=C\2/C3=C(C=C(C=C3)C(=O)N)NC2=O)/C4=CC=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tatake RJ, et al. Biochem Biophys Res Commun, 2008, 377(1), 120-125.
molnova catalog
related products
-
ERK-IN-3
ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
-
mSIRK
mSIRK (G-Protein βγ Binding Peptide) is a cell-permeable activator of ERK 1/2 with an EC50 of 2.5-5 μM.
-
Isomeranzin
Isomeranzin has anti-inflammatory activity, it suppresses inflammation by inhibiting M1 macrophage polarization through the p65, NF-κB and ERK pathway.
